FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200152149> ?p ?o ?g. }

• W4200152149 endingPage "2114" @default.
• W4200152149 startingPage "2098" @default.
• W4200152149 abstract "Glioblastoma (GBM) is the most common type of glioma and is uniformly fatal. Currently, tumour heterogeneity and mutation acquisition are major impedances for tailoring personalized therapy. We collected blood and tumour tissue samples from 25 GBM patients and 25 blood samples from healthy controls. Cell-free DNA (cfDNA) was extracted from the plasma of GBM patients and from healthy controls. Tumour DNA was extracted from fresh tumour samples. Extracted DNA was sequenced using a whole-genome sequencing procedure. We also collected 180 tumour DNA datasets from GBM patients publicly available at the TCGA/PANCANCER project. These data were analysed for mutations and gene-gene fusions that could be potential druggable targets. We found that plasma cfDNA concentrations in GBM patients were significantly elevated (22.6 ± 5 ng·mL-1 ), as compared to healthy controls (1.4 ± 0.4 ng·mL-1 ) of the same average age. We identified unique mutations in the cfDNA and tumour DNA of each GBM patient, including some of the most frequently mutated genes in GBM according to the COSMIC database (TP53, 18.75%; EGFR, 37.5%; NF1, 12.5%; LRP1B, 25%; IRS4, 25%). Using our gene-gene fusion database, ChiTaRS 5.0, we identified gene-gene fusions in cfDNA and tumour DNA, such as KDR-PDGFRA and NCDN-PDGFRA, which correspond to previously reported alterations of PDGFRA in GBM (44% of all samples). Interestingly, the PDGFRA protein fusions can be targeted by tyrosine kinase inhibitors such as imatinib, sunitinib, and sorafenib. Moreover, we identified BCR-ABL1 (in 8% of patients), COL1A1-PDGFB (8%), NIN-PDGFRB (8%), and FGFR1-BCR (4%) in cfDNA of patients, which can be targeted by analogues of imatinib. ROS1 fusions (CEP85L-ROS1 and GOPC-ROS1), identified in 8% of patient cfDNA, might be targeted by crizotinib, entrectinib, or larotrectinib. Thus, our study suggests that integrated analysis of cfDNA plasma concentration, gene mutations, and gene-gene fusions can serve as a diagnostic modality for distinguishing GBM patients who may benefit from targeted therapy. These results open new avenues for precision medicine in GBM, using noninvasive liquid biopsy diagnostics to assess personalized patient profiles. Moreover, repeated detection of druggable targets over the course of the disease may provide real-time information on the evolving molecular landscape of the tumour." @default.
• W4200152149 created "2021-12-31" @default.
• W4200152149 creator A5006513035 @default.
• W4200152149 creator A5008181776 @default.
• W4200152149 creator A5010606382 @default.
• W4200152149 creator A5013502164 @default.
• W4200152149 creator A5020728015 @default.
• W4200152149 creator A5020937838 @default.
• W4200152149 creator A5035830536 @default.
• W4200152149 creator A5060394772 @default.
• W4200152149 creator A5063259615 @default.
• W4200152149 creator A5069745813 @default.
• W4200152149 creator A5073692717 @default.
• W4200152149 creator A5076261774 @default.
• W4200152149 creator A5079212421 @default.
• W4200152149 creator A5083854534 @default.
• W4200152149 creator A5089940103 @default.
• W4200152149 date "2022-02-11" @default.
• W4200152149 modified "2023-10-16" @default.
• W4200152149 title "Detection of gene mutations and gene–gene fusions in circulating cell‐free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis" @default.
• W4200152149 cites W1513515886 @default.
• W4200152149 cites W1602305089 @default.
• W4200152149 cites W1810761522 @default.
• W4200152149 cites W1968667083 @default.
• W4200152149 cites W1969032819 @default.
• W4200152149 cites W1969418855 @default.
• W4200152149 cites W1989773675 @default.
• W4200152149 cites W2026099579 @default.
• W4200152149 cites W2030209606 @default.
• W4200152149 cites W2040068950 @default.
• W4200152149 cites W2048494621 @default.
• W4200152149 cites W2056753605 @default.
• W4200152149 cites W2064211887 @default.
• W4200152149 cites W2064469303 @default.
• W4200152149 cites W2082534286 @default.
• W4200152149 cites W2088660297 @default.
• W4200152149 cites W2092158132 @default.
• W4200152149 cites W2092741900 @default.
• W4200152149 cites W2110256992 @default.
• W4200152149 cites W2114843025 @default.
• W4200152149 cites W2119263822 @default.
• W4200152149 cites W2122769974 @default.
• W4200152149 cites W2124985265 @default.
• W4200152149 cites W2130410032 @default.
• W4200152149 cites W2137297899 @default.
• W4200152149 cites W2139861459 @default.
• W4200152149 cites W2142386866 @default.
• W4200152149 cites W2156576646 @default.
• W4200152149 cites W2162259262 @default.
• W4200152149 cites W2169810552 @default.
• W4200152149 cites W2198964395 @default.
• W4200152149 cites W2200085484 @default.
• W4200152149 cites W2258130809 @default.
• W4200152149 cites W2263206910 @default.
• W4200152149 cites W2289424772 @default.
• W4200152149 cites W2297327110 @default.
• W4200152149 cites W2302772453 @default.
• W4200152149 cites W2425000566 @default.
• W4200152149 cites W2436138214 @default.
• W4200152149 cites W2438112042 @default.
• W4200152149 cites W2462538267 @default.
• W4200152149 cites W2504612473 @default.
• W4200152149 cites W2516329646 @default.
• W4200152149 cites W2548559507 @default.
• W4200152149 cites W2559588208 @default.
• W4200152149 cites W2561544420 @default.
• W4200152149 cites W2613984329 @default.
• W4200152149 cites W2619288567 @default.
• W4200152149 cites W2728299672 @default.
• W4200152149 cites W2739357331 @default.
• W4200152149 cites W2889101235 @default.
• W4200152149 cites W2910019223 @default.
• W4200152149 cites W2919595708 @default.
• W4200152149 cites W2921241162 @default.
• W4200152149 cites W2969397082 @default.
• W4200152149 cites W2991020716 @default.
• W4200152149 cites W2997022986 @default.
• W4200152149 cites W3003373436 @default.
• W4200152149 cites W3003946104 @default.
• W4200152149 cites W3086597332 @default.
• W4200152149 cites W3166546774 @default.
• W4200152149 cites W4241797067 @default.
• W4200152149 doi "https://doi.org/10.1002/1878-0261.13157" @default.
• W4200152149 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34875133" @default.
• W4200152149 hasPublicationYear "2022" @default.
• W4200152149 type Work @default.
• W4200152149 citedByCount "10" @default.
• W4200152149 countsByYear W42001521492022 @default.
• W4200152149 countsByYear W42001521492023 @default.
• W4200152149 crossrefType "journal-article" @default.
• W4200152149 hasAuthorship W4200152149A5006513035 @default.
• W4200152149 hasAuthorship W4200152149A5008181776 @default.
• W4200152149 hasAuthorship W4200152149A5010606382 @default.
• W4200152149 hasAuthorship W4200152149A5013502164 @default.
• W4200152149 hasAuthorship W4200152149A5020728015 @default.
• W4200152149 hasAuthorship W4200152149A5020937838 @default.
• W4200152149 hasAuthorship W4200152149A5035830536 @default.
• W4200152149 hasAuthorship W4200152149A5060394772 @default.

• next